EP1685151A4 - NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS - Google Patents

NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS

Info

Publication number
EP1685151A4
EP1685151A4 EP04800514A EP04800514A EP1685151A4 EP 1685151 A4 EP1685151 A4 EP 1685151A4 EP 04800514 A EP04800514 A EP 04800514A EP 04800514 A EP04800514 A EP 04800514A EP 1685151 A4 EP1685151 A4 EP 1685151A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
brain damage
neural regeneration
regeneration peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04800514A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1685151A2 (en
Inventor
Frank Sieg
Thorsten Gorba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of EP1685151A2 publication Critical patent/EP1685151A2/en
Publication of EP1685151A4 publication Critical patent/EP1685151A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
EP04800514A 2003-10-31 2004-11-01 NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS Withdrawn EP1685151A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51601803P 2003-10-31 2003-10-31
US58504104P 2004-07-02 2004-07-02
US61627104P 2004-10-05 2004-10-05
PCT/US2004/036203 WO2005042561A2 (en) 2003-10-31 2004-11-01 Neural regeneration peptides and methods of use

Publications (2)

Publication Number Publication Date
EP1685151A2 EP1685151A2 (en) 2006-08-02
EP1685151A4 true EP1685151A4 (en) 2009-04-22

Family

ID=34557374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04800514A Withdrawn EP1685151A4 (en) 2003-10-31 2004-11-01 NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS

Country Status (3)

Country Link
EP (1) EP1685151A4 (ja)
JP (1) JP5026083B2 (ja)
WO (1) WO2005042561A2 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888635B1 (en) * 2005-05-06 2015-07-22 Curonz Holdings Company Limited Neural regeneration peptides and methods for their use
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
NZ565639A (en) * 2005-10-31 2012-03-30 Serono Lab Use of SDF-1 for the treatment and/or prevention of neurological diseases
WO2009051844A1 (en) 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Synthetic analogues of neural regeneration peptides
WO2013112002A1 (ko) * 2012-01-27 2013-08-01 의료법인 성광의료재단 뇌 손상 증세의 경감 또는 완화에 대한 바이오마커
WO2014017927A1 (en) * 2012-07-27 2014-01-30 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
JP2016514954A (ja) * 2013-03-08 2016-05-26 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 神経再生ペプチドおよびその使用
EP3054967A4 (en) * 2013-10-11 2017-04-19 Tarix Pharmaceuticals Ltd. Novel peptide compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (en) * 2001-08-24 2003-03-06 Neuronz Limited Neural regeneration peptide and methods for their use in treatment of brain damage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721464A4 (en) * 1993-09-01 1998-12-30 Start Technology Partnership NEURON REGULATOR FACTOR FOR PROMOTING NEURON SURVIVAL

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (en) * 2001-08-24 2003-03-06 Neuronz Limited Neural regeneration peptide and methods for their use in treatment of brain damage

Also Published As

Publication number Publication date
WO2005042561A2 (en) 2005-05-12
JP5026083B2 (ja) 2012-09-12
WO2005042561A3 (en) 2006-10-12
EP1685151A2 (en) 2006-08-02
JP2007511210A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
EP1641522A4 (en) Gastrointestinal methods and devices for use in the treatment of diseases
AU2003286611A8 (en) Cytomodulating peptides and methods for treating neurological disorders
EP1641378A4 (en) METHOD AND DEVICES FOR TREATING SKIN Lions
EP1640035A4 (en) HEART TREATMENT APPARATUS AND HEART TREATMENT METHOD
GB2398810B (en) Well treatment method and system
EP1680166A4 (en) METHOD AND DEVICE FOR THE TREATMENT OF HEART FAILURE
EP1928466A4 (en) PDT TREATMENT METHOD AGAINST CELLULITIS AND COSMETIC USE
EP1701664A4 (en) SYSTEM AND METHOD FOR PROCESSING A FABRIC
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL174185A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1662993A4 (en) METHODS AND APPARATUS FOR BIOIMPEDANCE
EP1761204A4 (en) IMPLANTABLE DEVICE FOR THE TREATMENT OF DISEASES AND METHODS OF USE
GB2397528B (en) Method and device for treatment of skin conditions
AU2003287909A8 (en) Electro-therapeutic device and method of electro-therapeutic treatment
AU2002335657A8 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
PL378465A1 (pl) Sposób i urządzenie do terapii leczniczej
EP1685151A4 (en) NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS
EP1718360A4 (en) METHOD AND SYSTEM FOR CUTANE / CAPILLARY TREATMENT
EP1606418A4 (en) METHODS OF DIAGNOSING AND TREATING EPILEPSY
EP1575993A4 (en) METHODS OF PATIENT TREATMENT AND THERAPEUTIC IDENTIFICATION
GB2431578B (en) Apparatus and method for use in the treatment of hair
EP1542654A4 (en) TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN
GB0410999D0 (en) Method and aparatus for electrode dressing
GB2404864B (en) Apparatus and method for stimulation of the human body
GB2406865B (en) Well treatment system and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060526

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/00 20060101ALI20061125BHEP

Ipc: A01N 37/18 20060101ALI20061125BHEP

Ipc: A01N 61/00 20060101AFI20061125BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20090319

17Q First examination report despatched

Effective date: 20100121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121030